INmune Bio
INMB
26 hedge funds and large institutions have $15M invested in INmune Bio in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 10 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
46% more capital invested
Capital invested by funds: $10.3M → $15M (+$4.73M)
1.03% less ownership
Funds ownership: 7.38% → 6.35% (-1%)
7% less funds holding
Funds holding: 28 → 26 (-2)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.05M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$536K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$435K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$218K |
| 5 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$2.58M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.03M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$760K |
| 4 |
Renaissance Technologies
New York
|
-$412K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$247K |
INMB Hedge Fund Activity: Q4 2020 in Review
26 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q4 2020, worth a combined $15M — up 46% from $10.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of INMB and 9 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $2.05M. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $2.58M sold.
- 26 institutional investors held INmune Bio (INMB) as of Q4 2020, down from 28 in Q3 2020.
- Funds reported $15M of INmune Bio stock for Q4 2020, up 46% quarter-over-quarter.
- 9 funds opened new INmune Bio positions in Q4 2020 and 10 closed out, a net change of -1 holder.
- The largest INmune Bio buyer in Q4 2020 was Ikarian Capital, an estimated $2.05M added.
- The largest INmune Bio seller in Q4 2020 was Granite Point Capital Management, an estimated $2.58M sold.
Based on aggregated 13F filings for Q4 2020.